Safety and efficacy of Kaffes intraductal self-expanding metal stents in the management of post-liver transplant anastomotic strictures

Table 3 Post-endoscopic retrograde cholangiopancreatography complications

Post-ERCP complications	3 months	6 months	P value
Any complication, n (%)	3 (6.1)	3 (9.1)	0.40
Pancreatitis, n (%)
Episodes	0 (0.0)	0 (0.0)	1.00
During Kaffes insertion
Prophylactic rectal indomethacin	2 (6.1)	4 (12.1)	0.40
Pancreatic duct cannulation	1 (3.0)	1 (3.0)	1.00
Pancreatic duct stent insertion1	1 (3.0)	0 (0.0)	0.32
Cholangitis, n (%)
Episodes	0 (0.0)	1 (3.0)	0.32
Prophylactic antibiotics at Kaffes insertion	30 (90.9)	29 (87.9)	0.69
Piperacillin/Tazobactam	20 (60.6)	25 (75.8)
Ciprofloxacin	1 (3.0)	0 (0.0)
Ceftriaxone	8 (24.2)	0 (0.0)
Other	1 (3.1)	4 (12.1)
Bleeding2	1 (3.3)	0 (0.0)	1.00
Admission3	2 (6.7)	3 (9.1)	0.31
Stent migration	1 (3.3)	0 (0.0)	0.29

¹Pancreatic duct stent inserted for same patient who had inadvertent duct cannulation.

²Bleeding due to gastric ulcer, unrelated to endoscopic retrograde cholangiopancreatography (ERCP) procedure.

³Case with bleeding was included even though unrelated to ERCP procedure.

ERCP: Endoscopic retrograde cholangiopancreatography.